The Immune Deficiency Foundation (US) participated in the Workshop on Immune Globulin Potency in the 21st Century, on November 8-9, 2017. The workshop explored the ramifications for people with primary immunodeficiency diseases (PID) as certain measured antibody titers continue to drop in immunoglobulin (IG) replacement products in the U.S.
For those with antibody deficiencies, such as Common Variable Immune Deficiency and X-linked Agammaglobulinemia, among other types of PID, immunoglobulin (IG) therapy is a lifesaving and lifelong treatment. Since that therapy is derived from source plasma, IDF and its fellow stakeholders are always concerned about ensuring that IG products—those currently available, as well as those manufactured in the future—will contain sufficient levels of antibodies to provide protection against infectious agents of special concern to individuals who have antibody deficiencies.
The workshop was organized in cooperation with the U.S. Center for Biologics Evaluation and Research (CBER) of the Food and Drug Administration (FDA), the Plasma Protein Therapeutics Association (PPTA), and the National Institute of Allergy and Infectious Diseases (NIAID).
To learn more about the workshop, go to: http://bit.ly/Igpotencyworkshop.